HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wheat, Hi-Tech Fined $40M For Violating Court Order On FTC Complaint

This article was originally published in The Rose Sheet

Executive Summary

Following his recent arrest in a separate federal enforcement, Hi-Tech Pharmaceuticals CEO Jared Wheat and his firm are fined $40m for violating a 2008 court order on an FTC complaint about fraudulent weight loss claims. The financial sanction is justified by a “pattern of contemptuous conduct,” the judge said.

You may also be interested in...



Wheat, Hi-Tech On Hook For $40M As Appeals Court Rejects Argument Against FTC Authority

“The defendants’ argument rests on a misunderstanding of the basis for the contempt judgment” which were “imposed because the defendants violated the injunction,” says three-judge 11th Circuit panel.

US COVID-19 Claim Warnings Continue; Hi-Tech’s Problems Extend To Undeclared Allergens

Natural Adventure and PYRLess Group are latest firms to learn FDA, FTC continue monitoring the market for claims promoting supplements as COVID-19 treatments. Hi-Tech Pharmaceuticals recalls APS Nutrition Isomorph 28 and iForce Nutrition Mass Gainz due to undeclared allergens.

Supplement Firm Hi-Tech Pays For Another Round Of Refunds In FTC’s 15-Year Litigation

FTC is mailing 143,636 refund checks totaling more than $8.5m to consumers who bought three supplements marketed with false and misleading advertising by Hi-Tech Pharmaceuticals and several related companies.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121256

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel